{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:14:56Z","timestamp":1774534496048,"version":"3.50.1"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T00:00:00Z","timestamp":1566777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0221500","type":"journal-article","created":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T17:26:05Z","timestamp":1566840365000},"page":"e0221500","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":23,"title":["Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2033-736X","authenticated-orcid":true,"given":"Lars J.","family":"Kjerpeseth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randi","family":"Selmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inger","family":"Ariansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d8ystein","family":"Karlstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanne","family":"Ellekj\u00e6r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Skovlund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,8,26]]},"reference":[{"issue":"10","key":"pone.0221500.ref001","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/europace\/eus305","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"14","author":"AJ Camm","year":"2012","journal-title":"Europace"},{"issue":"10","key":"pone.0221500.ref002","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","article-title":"Systematic overview of warfarin and its drug and food interactions","volume":"165","author":"AM Holbrook","year":"2005","journal-title":"Arch Intern Med"},{"issue":"12","key":"pone.0221500.ref003","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"SJ Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0221500.ref004","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"MR Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0221500.ref005","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"CB Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"19","key":"pone.0221500.ref006","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"European Association for Cardio-Thoracic S","year":"2010","journal-title":"Eur Heart J"},{"issue":"11","key":"pone.0221500.ref007","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00228-017-2296-1","article-title":"Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015","volume":"73","author":"LJ Kjerpeseth","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"pone.0221500.ref008","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s00228-018-2540-3","article-title":"Risk factors for stroke and choice of oral anticoagulant in atrial fibrillation","volume":"74","author":"LJ Kjerpeseth","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"pone.0221500.ref009","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.amjmed.2015.05.044","article-title":"National Trends in Ambulatory Oral Anticoagulant Use","volume":"128","author":"GD Barnes","year":"2015","journal-title":"Am J Med"},{"issue":"12","key":"pone.0221500.ref010","first-page":"899","article-title":"Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark","volume":"38","author":"K Gadsboll","year":"2017","journal-title":"Eur Heart J"},{"issue":"3","key":"pone.0221500.ref011","doi-asserted-by":"crossref","first-page":"e018180","DOI":"10.1136\/bmjopen-2017-018180","article-title":"Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases","volume":"8","author":"L Huiart","year":"2018","journal-title":"BMJ Open"},{"issue":"9","key":"pone.0221500.ref012","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/bcp.13299","article-title":"Trends in the prescription of novel oral anticoagulants in UK primary care","volume":"83","author":"SY Loo","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"pone.0221500.ref013","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.amjmed.2014.05.013","article-title":"Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications","volume":"127","author":"NR Desai","year":"2014","journal-title":"Am J Med"},{"issue":"20","key":"pone.0221500.ref014","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1016\/j.jacc.2017.03.540","article-title":"Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation","volume":"69","author":"LN Marzec","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"pone.0221500.ref015","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bcp.13150","article-title":"Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis","volume":"83","author":"J Komen","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"pone.0221500.ref016","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.thromres.2016.02.023","article-title":"Antithrombotic therapy in patients with non-valvular atrial fibrillation in Southern Sweden: A population-based cohort study","volume":"140","author":"N Mochalina","year":"2016","journal-title":"Thromb Res"},{"issue":"11","key":"pone.0221500.ref017","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrcardio.2014.118","article-title":"Global epidemiology of atrial fibrillation","volume":"11","author":"F Rahman","year":"2014","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"pone.0221500.ref018","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00228-017-2374-4","article-title":"Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments","volume":"74","author":"AK Eek","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"pone.0221500.ref019","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/hep.21404","article-title":"Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies","volume":"44","author":"HT Sorensen","year":"2006","journal-title":"Hepatology"},{"issue":"2","key":"pone.0221500.ref020","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.clpt.6100249","article-title":"Developments in post-marketing comparative effectiveness research","volume":"82","author":"S. Schneeweiss","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"pone.0221500.ref021","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1161\/STROKEAHA.117.017549","article-title":"Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis","volume":"48","author":"G Ntaios","year":"2017","journal-title":"Stroke"},{"issue":"4","key":"pone.0221500.ref022","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8040554","article-title":"Effectiveness and Safety of Direct Oral Anticoagulants versus Vitamin K Antagonists for People Aged 75 Years and over with Atrial Fibrillation: A Systematic Review and Meta-Analyses of Observational Studies","volume":"8","author":"A Mitchell","year":"2019","journal-title":"Journal of clinical medicine"},{"issue":"2","key":"pone.0221500.ref023","first-page":"129","article-title":"Establishment of the nationwide Norwegian Prescription Database (NorPD)\u2014new opportunities for research in pharmacoepidemiology in Norway","volume":"18","author":"K. Furu","year":"2008","journal-title":"Nor J Epidemiol"},{"issue":"2","key":"pone.0221500.ref024","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1742-7843.2009.00494.x","article-title":"The Nordic countries as a cohort for pharmacoepidemiological research","volume":"106","author":"K Furu","year":"2010","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"pone.0221500.ref025","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/ehjcvp\/pvw031","article-title":"A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants","volume":"3","author":"S Halvorsen","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"6","key":"pone.0221500.ref026","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/clpt.2011.235","article-title":"Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development","volume":"90","author":"S Schneeweiss","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"pone.0221500.ref027","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"WA Ray","year":"2003","journal-title":"Am J Epidemiol"},{"issue":"4","key":"pone.0221500.ref028","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"JL Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"issue":"8","key":"pone.0221500.ref029","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/pds.4216","article-title":"Refining estimates of prescription durations by using observed covariates in pharmacoepidemiological databases: an application of the reverse waiting time distribution","volume":"26","author":"H Stovring","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"pone.0221500.ref030","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/pds.4217","article-title":"Estimating medication stopping fraction and real-time prevalence of drug use in pharmaco-epidemiologic databases. An application of the reverse waiting time distribution","volume":"26","author":"H Stovring","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"pone.0221500.ref031","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/pds.4581","article-title":"Empirical validation of the reverse parametric waiting time distribution and standard methods to estimate prescription durations for warfarin","volume":"27","author":"JM Thrane","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"pone.0221500.ref032","doi-asserted-by":"crossref","first-page":"e00900","DOI":"10.1002\/brb3.900","article-title":"Validation of intracranial hemorrhage in the Norwegian Patient Registry","volume":"8","author":"LR Oie","year":"2018","journal-title":"Brain Behav"},{"issue":"8","key":"pone.0221500.ref033","doi-asserted-by":"crossref","first-page":"e0135834","DOI":"10.1371\/journal.pone.0135834","article-title":"Validity of Diagnostic Codes for Acute Stroke in Administrative Databases: A Systematic Review","volume":"10","author":"N McCormick","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"pone.0221500.ref034","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies","volume":"21","author":"M Lipsitch","year":"2010","journal-title":"Epidemiology"},{"issue":"11","key":"pone.0221500.ref035","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/thoraxjnl-2013-204282","article-title":"Risk factors for community-acquired pneumonia in adults in Europe: a literature review","volume":"68","author":"A Torres","year":"2013","journal-title":"Thorax"},{"issue":"10","key":"pone.0221500.ref036","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00228-017-2289-0","article-title":"Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs","volume":"73","author":"J Komen","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"pone.0221500.ref037","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/joim.12628","article-title":"Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant?","volume":"282","author":"A Gundlund","year":"2017","journal-title":"J Intern Med"},{"key":"pone.0221500.ref038","article-title":"Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study","author":"T Forslund","year":"2017","journal-title":"Europace"},{"key":"pone.0221500.ref039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/POR.S156521","article-title":"Real-world effectiveness and safety of oral anticoagulation strategies in atrial fibrillation: a cohort study based on a German claims dataset","volume":"9","author":"S Mueller","year":"2018","journal-title":"Pragmatic and observational research"},{"issue":"22","key":"pone.0221500.ref040","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"RP Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0221500.ref041","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1213\/ane.0b013e31819bceb1","article-title":"The role of tissue factor and factor VIIa in hemostasis","volume":"108","author":"N. Mackman","year":"2009","journal-title":"Anesth Analg"},{"issue":"8","key":"pone.0221500.ref042","doi-asserted-by":"crossref","first-page":"e0202575","DOI":"10.1371\/journal.pone.0202575","article-title":"Risk of intracranial hemorrhage (RICH) in users of oral antithrombotic drugs: Nationwide pharmacoepidemiological study","volume":"13","author":"S Gulati","year":"2018","journal-title":"PLoS One"},{"issue":"6","key":"pone.0221500.ref043","first-page":"1290","article-title":"A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system","volume":"114","author":"TC Villines","year":"2015","journal-title":"Thromb Haemost"},{"key":"pone.0221500.ref044","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.ijcard.2015.11.067","article-title":"'Real-world' haemorrhagic rates for warfarin and dabigatran using population-level data in New Zealand","volume":"203","author":"PS Nishtala","year":"2016","journal-title":". Int J Cardiol"},{"issue":"4","key":"pone.0221500.ref045","doi-asserted-by":"crossref","first-page":"e001798","DOI":"10.1161\/JAHA.115.001798","article-title":"Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study","volume":"4","author":"JC Lauffenburger","year":"2015","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"pone.0221500.ref046","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40273-014-0152-z","article-title":"Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation","volume":"32","author":"T Wisloff","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"pone.0221500.ref047","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1161\/STROKEAHA.118.021990","article-title":"Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants","volume":"49","author":"T Forslund","year":"2018","journal-title":"Stroke"},{"issue":"2","key":"pone.0221500.ref048","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jamainternmed.2013.1579","article-title":"Temporal trends in ischemic stroke and anticoagulation therapy among Medicare patients with atrial fibrillation: a 15-year perspective (1992\u20132007)","volume":"173","author":"GR Shroff","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"2","key":"pone.0221500.ref049","doi-asserted-by":"crossref","first-page":"e000521","DOI":"10.1161\/JAHA.113.000521","article-title":"Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial","volume":"3","author":"JP Piccini","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"22","key":"pone.0221500.ref050","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1161\/CIRCULATIONAHA.112.142158","article-title":"Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation","volume":"127","author":"L Wallentin","year":"2013","journal-title":"Circulation"},{"issue":"9745","key":"pone.0221500.ref051","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(10)61194-4","article-title":"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial","volume":"376","author":"L Wallentin","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"pone.0221500.ref052","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000107789","article-title":"Atrial fibrillation and antithrombotic therapy in a 75-year-old population","volume":"109","author":"A Tveit","year":"2008","journal-title":"Cardiology"},{"key":"pone.0221500.ref053","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2147\/CLEP.S103346","article-title":"Validation of self-reported and hospital-diagnosed atrial fibrillation: the HUNT study","volume":"8","author":"V Malmo","year":"2016","journal-title":"Clin Epidemiol"},{"issue":"2","key":"pone.0221500.ref054","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1403494815621641","article-title":"Comparison of the validity of stroke diagnoses in a medical quality register and an administrative health register","volume":"44","author":"T Varmdal","year":"2016","journal-title":"Scand J Public Health"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0221500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T02:59:07Z","timestamp":1588993147000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0221500"}},"subtitle":[],"editor":[{"given":"Pablo","family":"Garcia de Frutos","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,8,26]]},"references-count":54,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0221500","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,26]]}}}